HVSEN BIOTECH(SZ:300871)2025-06-12 10:38Group 1: Financial Performance - In 2024, the company's raw material drug exports achieved sales revenue of 63.39 million yuan, a year-on-year increase of 155.71% [2] - The net profit for Q1 2025 reached 44.50 million yuan, representing a year-on-year growth of 371.23% [5] - The export revenue for Q1 2025 decreased by 10.92% compared to Q4 2024 [7] Group 2: Product Development and Market Strategy - The company is focusing on increasing investment in pet drug research and market channel development, with a complete product matrix already established [3] - The Vietnam production base has a designed capacity of 1,500 tons per year, primarily producing chemical drug formulations [4] - The company is actively exploring overseas markets and implementing a "go out" strategy to mitigate domestic business cycle impacts [5] Group 3: Market Position and Competitive Strategy - The pet segment currently has a small revenue share but is showing a good growth trend [3] - The company is enhancing its competitive edge by deepening the integration of raw materials and formulations, optimizing product performance, and improving the industry chain structure [7] - The company does not currently engage in the pet hospital and vaccine business but is monitoring the market for potential opportunities [6]